Evidence map›Paper›PMID 39702900›Full record

ArticlePediatric blood & cancer2025

Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study-5 and Children's Oncology Group Study AREN0321.

James I Geller, Lindsay A Renfro, Paul E Grundy, Elizabeth J Perlman, John A Kalapurakal, Peter F Ehrlich, Jackie Biegel, Vicki Huff, Anne B Warwick, Arnold Paulino and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

James I GellerDivision of Pediatric Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0001-5181-116X
Lindsay A RenfroDivision of Biostatistics, University of Southern California and Children's Oncology Group, Los Angeles, California, USA.
Paul E GrundyDivision of Immunology, Hematology, Oncology, Palliative Care, and Environmental Interactions, University of Alberta, Edmonton, Alberta, Canada.
Elizabeth J PerlmanDepartment of Pathology and Laboratory Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
John A KalapurakalDepartment of Radiation Oncology, Northwestern University, Chicago, Illinois, USA.
Peter F EhrlichSection of Pediatric Surgery, CS Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0001-6161-1815
Jackie BiegelKeck School of Medicine, University of Southern California, Los Angeles, California, USA.
Vicki HuffDepartment of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anne B WarwickDepartment of Pediatrics, F. Edward Hébert School of Medicine, Uniformed Services University, Bethesda, Maryland, USA.
Arnold PaulinoMD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-0269-3045
Elizabeth A MullenBoston Children's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Najat C DawDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fredric A HofferDepartment of Radiology, Fred Hutchison Cancer Center, University of Washington, Seattle, Washington, USA.
Zelig TochnerDepartment of Radiation Oncology, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kenneth GowDivision of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, University of Washington, Seattle, Washington, USA.
Eric GratiaseviCore Healthcare, Bluffton, South Carolina, USA.
Deborah A WardDepartment of Pharmaceutical Services, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
James R AndersonUniversity of Nebraska Medical Center, Omaha, Nebraska, USA.
Conrad V FernandezDivision of Pediatric Hematology Oncology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada.
Jeffrey S DomeDivision of Oncology, Children's National Hospital and Department of Pediatrics, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
Development, review, and conduct of Children's Oncology Group (COG) Clinical TrialsR50CA275931 · NCI · CHILDREN'S RESEARCH INSTITUTE · PI JEFFREY S DOME · 2023 to 2026
$569k
NCI NIH HHS R50 CA275931NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIH HHSSt. Baldrick's FoundationUS Public Health Service CA-42326
6 · The paper itself

Abstract

purposeNational Wilms Tumor Study-5 (NWTS-5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT). PATIENTS AND

methodsEligible patients with RTK were enrolled prospectively on NWTS-5 (1995-2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005-2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH-1 or dose-reduced Revised UH-1). We report event-free survival (EFS) and overall survival (OS) from each study.

resultsThirty patients received Regimen RTK on NWTS-5; on AREN0321, 20 received UH-1 and 19 received Revised UH-1. Patient and disease characteristics were statistically similar between studies. Patients on AREN0321 had significantly improved EFS and OS compared to those on NWTS-5 (4-year EFS = 23.1% vs. 16.7%; p = 0.020; 4-year OS = 30.6% vs. 20.0%; p = 0.014), mostly driven by patients with Stage I/II disease (p = 0.05). Median time to an event was 3.6 months on NWTS-5 compared to 7.2 months on AREN0321. There were no differences in EFS or OS by revised versus original Regimen UH-1 on AREN0321, or by renal versus extra-renal primary disease when the studies were pooled.

conclusionsThe more intensive treatment regimen used on AREN0321 improved EFS and OS overall, a result driven by patients with Stage I/II disease. Despite this improvement, outcomes for patients with rhabdoid tumor remain unsatisfactory and there is a need for novel therapeutic strategies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsKidney NeoplasmsRhabdoid TumorSoft Tissue NeoplasmsAdolescentCarboplatinChildChild, PreschoolCyclophosphamideDoxorubicinEtoposideFemaleFollow-Up StudiesHumansInfantMaleCarboplatinCyclophosphamideDoxorubicinEtoposideVincristinechemotherapypediatric oncologyrenalrhabdoid tumortumors

Identifiers

PMID39702900
PMCPMC11801664

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.